Source link : https://www.newshealth.biz/health-news/idh-inhibitor-activity-in-brain-cancer-persists-with-longer-follow-up/
HOUSTON — Progression-free survival (PFS) in IDH-mutant low-grade glioma remained twice as high in adults who received vorasidenib (Voranigo) after surgery versus placebo, according to a follow-up analysis of a pivotal clinical trial. After a median follow-up of 20 months, median PFS had yet to be reached in patients randomized to vorasidenib (lower range of […]
Author : News Health
Publish date : 2024-11-24 20:00:07
Copyright for syndicated content belongs to the linked Source.